Wellgistics Health, Inc. Announces Closing of $4.0 Million Initial Public Offering
Wellgistics Health has successfully completed its Initial Public Offering (IPO), raising $4.0 million in gross proceeds through the sale of 888,889 shares of common stock at $4.50 per share. The company's shares began trading on the Nasdaq Capital Market under the ticker symbol WGRX on February 21, 2025.
The firm commitment offering was underwritten by Craft Capital Management and D. Boral Capital The company plans to use the net proceeds for general corporate purposes, including working capital, marketing initiatives, and capital expenditures. The IPO registration statement was declared effective by the SEC on February 14, 2025.
Wellgistics Health operates as a holding company focused on healthcare technology and pharmaceutical services, with both existing operations and planned strategic business initiatives.
Wellgistics Health ha completato con successo la sua Offerta Pubblica Iniziale (IPO), raccogliendo 4,0 milioni di dollari in proventi lordi attraverso la vendita di 888.889 azioni ordinarie a 4,50 dollari per azione. Le azioni della società hanno iniziato a essere scambiate sul Nasdaq Capital Market con il simbolo ticker WGRX il 21 febbraio 2025.
L'offerta con impegno fermo è stata garantita da Craft Capital Management e D. Boral Capital. La società prevede di utilizzare i proventi netti per scopi aziendali generali, inclusi capitale circolante, iniziative di marketing e spese in conto capitale. La dichiarazione di registrazione dell'IPO è stata dichiarata efficace dalla SEC il 14 febbraio 2025.
Wellgistics Health opera come una holding focalizzata sulla tecnologia sanitaria e sui servizi farmaceutici, con operazioni esistenti e iniziative aziendali strategiche pianificate.
Wellgistics Health ha completado con éxito su Oferta Pública Inicial (IPO), recaudando 4.0 millones de dólares en ingresos brutos a través de la venta de 888,889 acciones ordinarias a 4.50 dólares por acción. Las acciones de la compañía comenzaron a cotizar en el Nasdaq Capital Market bajo el símbolo de cotización WGRX el 21 de febrero de 2025.
La oferta con compromiso firme fue suscrita por Craft Capital Management y D. Boral Capital. La empresa planea utilizar los ingresos netos para fines corporativos generales, incluyendo capital de trabajo, iniciativas de marketing y gastos de capital. La declaración de registro de la IPO fue declarada efectiva por la SEC el 14 de febrero de 2025.
Wellgistics Health opera como una empresa matriz enfocada en tecnología de salud y servicios farmacéuticos, con operaciones existentes e iniciativas comerciales estratégicas planificadas.
Wellgistics Health는 상장공모(IPO)를 성공적으로 완료하여 400만 달러의 총 수익을 올렸습니다. 이는 주당 4.50달러에 888,889주를 판매한 결과입니다. 회사의 주식은 2025년 2월 21일 Nasdaq Capital Market에서 WGRX라는 티커 심볼로 거래를 시작했습니다.
이 확정 공모는 Craft Capital Management와 D. Boral Capital이 인수했습니다. 회사는 순수익을 일반 기업 목적, 즉 운영 자본, 마케팅 이니셔티브 및 자본 지출에 사용할 계획입니다. IPO 등록 신청서는 2025년 2월 14일 SEC에 의해 유효하다고 선언되었습니다.
Wellgistics Health는 의료 기술 및 제약 서비스에 중점을 둔 지주 회사로, 기존 운영 및 계획된 전략적 사업 이니셔티브를 가지고 있습니다.
Wellgistics Health a réussi à compléter son Offre Publique Initiale (IPO), levant 4,0 millions de dollars de recettes brutes grâce à la vente de 888 889 actions ordinaires à 4,50 dollars par action. Les actions de l'entreprise ont commencé à être négociées sur le Nasdaq Capital Market sous le symbole boursier WGRX le 21 février 2025.
L'offre avec engagement ferme a été souscrite par Craft Capital Management et D. Boral Capital. L'entreprise prévoit d'utiliser les produits nets à des fins d'entreprise générales, y compris le fonds de roulement, les initiatives de marketing et les dépenses d'investissement. La déclaration d'enregistrement de l'IPO a été déclarée effective par la SEC le 14 février 2025.
Wellgistics Health opère en tant que société holding axée sur la technologie de la santé et les services pharmaceutiques, avec des opérations existantes et des initiatives commerciales stratégiques planifiées.
Wellgistics Health hat erfolgreich ihr Börsengang (IPO) abgeschlossen und dabei 4,0 Millionen Dollar an Bruttoeinnahmen durch den Verkauf von 888.889 Stammaktien zu 4,50 Dollar pro Aktie gesammelt. Die Aktien des Unternehmens wurden am Nasdaq Capital Market unter dem Tickersymbol WGRX am 21. Februar 2025 gehandelt.
Das feste Angebot wurde von Craft Capital Management und D. Boral Capital gezeichnet. Das Unternehmen plant, die Nettomittel für allgemeine Unternehmenszwecke zu verwenden, einschließlich Betriebskapital, Marketinginitiativen und Investitionsausgaben. Die Registrierungsanmeldung für das IPO wurde am 14. Februar 2025 von der SEC für wirksam erklärt.
Wellgistics Health agiert als Holdinggesellschaft, die sich auf Gesundheitstechnologie und pharmazeutische Dienstleistungen konzentriert, mit bestehenden Betrieben und geplanten strategischen Geschäftsinitiativen.
- Successfully raised $4.0 million through IPO
- Achieved Nasdaq Capital Market listing
- Secured firm commitment underwriting from two financial institutions
- Small offering size of only $4.0 million may limit growth potential
- Proceeds will be reduced by underwriting discounts and expenses
Insights
This
The offering price of
The allocation of proceeds towards working capital, marketing, and capital expenditures indicates a focus on organic growth rather than immediate acquisitions. This approach could provide better risk-adjusted returns in the current market environment, where healthcare technology valuations have become more rational.
The selection of the Nasdaq Capital Market aligns with the company's size and provides a solid foundation for potential future capital raises. However, the success of this strategy will heavily depend on management's ability to effectively deploy capital and demonstrate operational synergies across their planned healthcare technology and pharmaceutical services portfolio.
Tampa, Florida, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the closing of its initial public offering (the "Offering") of 888,889 shares of its common stock at a public offering price of
The Company received
The Offering was conducted on a firm commitment basis. Craft Capital Management LLC and D. Boral Capital LLC acted as underwriters for the Offering (the “Underwriters”). Dykema Gossett PLLC acted as counsel to the Company, and Sichenzia Ross Ferrance Carmel LLP acted as counsel to the Underwriters in connection with the Offering.
A registration statement on Form S-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333-280925) and was declared effective by the SEC on February 14, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering may be obtained from Craft Capital Management LLC by standard mail to Craft Capital Management LLC, 377 Oak St, Lower Concourse, Garden City, NY 11530 or by email at info@craftcm.com, or by telephone at +1(516)-833-1325; or from D. Boral Capital LLC by standard mail to D. Boral Capital LLC, 590 Madison Ave 39th Floor, New York, NY 10022, or by email at info@dboralcapital.com, or by telephone at +1(212)-970-5150. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC's website at www.sec.gov.
This press release has been prepared for informational purposes only and shall not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Wellgistics Health, Inc.
Wellgistics Health is a holding company for existing and future planned operating companies centered around healthcare technology and pharmaceutical services. It seeks to be a micro health ecosystem, with a portfolio of companies consisting of a technology platform, pharmacy, and wholesale operations that provide novel prescription hub and clinical services. Wellgistics Health is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, Wellgistics Health intends to shift the dynamic of pharmaceutical care to revolve around the patient for a wide range of therapeutic conditions by offering a full spectrum of integrated solutions as a result of leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from “specialty-lite” to general maintenance conditions. For more information, please visit the Company’s website: https://wellgisticshealth.com/
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the expected trading of its common stock on the Nasdaq Capital Market and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
IR@wellgistics.com
FAQ
How much did Wellgistics Health (WGRX) raise in its IPO?
When did WGRX stock begin trading on Nasdaq?
What is the IPO price for Wellgistics Health (WGRX) shares?
How will Wellgistics Health use the IPO proceeds?
Who were the underwriters for the WGRX IPO?
